142 related articles for article (PubMed ID: 38723212)
21. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
22. [New progress of study on hematopoietic stem cell transplantation for myelodysplastic syndromes].
Wu B; Wei Y; Zhang Q
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):510-3. PubMed ID: 22541129
[TBL] [Abstract][Full Text] [Related]
23. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
24. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
25. The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation.
Hou C; Zhou L; Yang M; Jiang S; Shen H; Zhu M; Chen J; Miao M; Xu Y; Wu D
Front Oncol; 2021; 11():700234. PubMed ID: 34422653
[TBL] [Abstract][Full Text] [Related]
26. [Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes].
Gournay V; Robin M
Bull Cancer; 2023 Nov; 110(11):1168-1175. PubMed ID: 37516649
[TBL] [Abstract][Full Text] [Related]
27. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
Cutler CS; Lee SJ; Greenberg P; Deeg HJ; Pérez WS; Anasetti C; Bolwell BJ; Cairo MS; Gale RP; Klein JP; Lazarus HM; Liesveld JL; McCarthy PL; Milone GA; Rizzo JD; Schultz KR; Trigg ME; Keating A; Weisdorf DJ; Antin JH; Horowitz MM
Blood; 2004 Jul; 104(2):579-85. PubMed ID: 15039286
[TBL] [Abstract][Full Text] [Related]
28. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.
Aguirre LE; Al Ali N; Sallman DA; Ball S; Jain AG; Chan O; Tinsley-Vance SM; Kuykendall A; Sweet K; Lancet JE; Padron E; Komrokji RS
Leukemia; 2023 Jul; 37(7):1530-1539. PubMed ID: 37147425
[TBL] [Abstract][Full Text] [Related]
29. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
[TBL] [Abstract][Full Text] [Related]
30. Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
Montoro J; Pomares H; Villacampa G; Merchán B; Molero A; Alonso E; Gallur L; Grau J; Salamero O; Roldán E; Saumell S; Ortega M; Sureda A; Bosch F; Arnan M; Valcárcel D
Leuk Lymphoma; 2019 Jun; 60(6):1522-1527. PubMed ID: 30499738
[TBL] [Abstract][Full Text] [Related]
31. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
32. Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.
Yahng SA; Jeon YW; Yoon JH; Shin SH; Lee SE; Choi YS; Kim DY; Lee JH; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Lee JW; Lee KH; Min WS; Lee JH; Kim YJ
Bone Marrow Transplant; 2017 Apr; 52(4):522-531. PubMed ID: 27892952
[TBL] [Abstract][Full Text] [Related]
33. Treatment strategies for myelodysplastic syndrome in 2021.
Bělohlávková P
Vnitr Lek; 2021; 67(3):150-155. PubMed ID: 34171954
[TBL] [Abstract][Full Text] [Related]
34. Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome.
Danielson N; Byrne M
Curr Hematol Malig Rep; 2020 Aug; 15(4):268-275. PubMed ID: 32125608
[TBL] [Abstract][Full Text] [Related]
35. Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.
Ustun C; Trottier BJ; Sachs Z; DeFor TE; Shune L; Courville EL; Holtan SG; Dolan M; Weisdorf DJ; Warlick ED
Biol Blood Marrow Transplant; 2015 May; 21(5):866-72. PubMed ID: 25620751
[TBL] [Abstract][Full Text] [Related]
36. [Outcomes of 138 myelodysplastic syndrome patients with HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation].
Wang QQ; Liu ZX; Zhao XL; Zhang GX; Yao JF; Zheng XH; Zhang LN; Shen YY; Zhao XL; He Y; Huang Y; Zhang RL; Wei JL; Ma QL; Pang AM; Yang DL; Zhai WH; Jiang EL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):132-137. PubMed ID: 32135630
[No Abstract] [Full Text] [Related]
37. [Clinical Efficacy of the MDS Patients Treated by Allo-HSCT].
Wang QY; Dong YJ; Wang Q; Liu W; Sun YH; Yin Y; Liang ZY; Xu WL; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):172-180. PubMed ID: 33554815
[TBL] [Abstract][Full Text] [Related]
38. [The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome].
Zhao T; Huang X; Liu D; Wang J; Zhang X; Wang Y; Han W; Chen H; Chen Y; Wang F; Liu K; Xu L
Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):89-93. PubMed ID: 24767157
[TBL] [Abstract][Full Text] [Related]
39. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
